Financial Performance Summary

Q2 FY27 Financial Results (₹ Crore, except EPS)

  • Revenue: ₹2,206 Cr, up 33% YoY from ₹1,653 Cr in Q2 FY26
  • Gross Margins: 63.0%, improved by 3.1 percentage points from 59.9% in Q2 FY26
  • EBITDA: ₹762 Cr, up 78% YoY from ₹429 Cr in Q2 FY26
  • EBITDA Margins: 34.5%, expanded by 8.5 percentage points from 26.0% in Q2 FY26
  • PBT: ₹592 Cr, up 119% YoY from ₹270 Cr in Q2 FY26
  • Net Profit: ₹441 Cr, up 126% YoY from ₹195 Cr in Q2 FY26
  • EPS (Diluted): ₹8.2, up 128% YoY from ₹3.6 in Q2 FY26

H1 FY27 Financial Results (₹ Crore, except EPS)

  • Revenue: ₹4,233 Cr, up 31% YoY from ₹3,223 Cr in H1 FY26
  • Gross Margins: 62.9%, improved by 3.3 percentage points from 59.6% in H1 FY26
  • EBITDA: ₹1,406 Cr, up 72% YoY from ₹818 Cr in H1 FY26
  • EBITDA Margins: 33.2%, expanded by 7.8 percentage points from 25.4% in H1 FY26
  • PBT: ₹1,073 Cr, up 117% YoY from ₹494 Cr in H1 FY26
  • Net Profit: ₹809 Cr, up 126% YoY from ₹358 Cr in H1 FY26
  • EPS (Diluted): ₹15.0, up 127% YoY from ₹6.6 in H1 FY26

Divisional Revenue Performance

CDMO Division - Small Molecules

  • H1 FY27 Revenue: ₹1,710 Cr, up 77% YoY
  • Q2 FY27 Revenue: ₹875 Cr, up 86% YoY
  • Driven by advancing late-stage clinical projects, commercial API supplies, and ramp-up of new assets

CDMO Division - Bio (Large Molecules)

  • H1 FY27 Revenue: ₹64 Cr, down 16% YoY
  • Q2 FY27 Revenue: ₹29 Cr, down 38% YoY (due to campaign phasing)
  • LB-4 Fermentation manufacturing unit (>400kL) progressing, set for commissioning by Q3 FY27

Affordable Medicines Division

  • H1 FY27 Revenue: ₹2,459 Cr, up 13% YoY
  • Q2 FY27 Revenue: ₹1,302 Cr, up 15% YoY
  • ARV Revenue (API and FDF combined): ₹1,404 Cr in H1, up 2% YoY
  • API Revenue: ₹1,280 Cr in H1, up 2% YoY
  • FDF Revenue: ₹1,179 Cr in H1, up 27% YoY

Strategic Investments and Acquisitions

Acquisition of Galenvs Sciences

  • Signed definitive agreement on October 29, 2026 to acquire 60% equity stake
  • Pre-money valuation: USD 3.50 million
  • Total investment: USD 3.75 million (includes primary infusion of USD 2.75 million)
  • Galenvs Sciences is a Montréal, Québec, Canada-based biotechnology company specializing in precision magnetic nanoparticles and DNA/RNA technologies
  • Expected to strengthen Laurus' oligonucleotide development and manufacturing capabilities

Acquisition of SI &C Resins

  • Signed definitive agreement to acquire 52% stake
  • Peptide-resin technology focused company
  • Enhances supply chain security and peptides manufacturing competitiveness

Operational Highlights

Capacity Expansion

  • First commercial scale peptide plant operationalized in Vizag with >16,000L Solid Phase Peptide Synthesis (SPPS) capacity
  • Additional capacity expansion already in progress to address surging peptide therapeutics demand
  • Multiple large-scale API capacity construction in Vizag making good progress
  • KRKA JV formulation site: Phase-I production blocks to open in mid-2027 focusing on High Potent and General OSD capability

R&D Investments

  • H1 FY27 R&D investment: ₹183 Cr (4.3% of Revenue), up 34% YoY
  • Q2 FY27 R&D investment: ₹65 Cr (2.9% of Revenue)
  • Increased spending due to development efforts toward building Advanced Biologics infrastructure (Gene Therapy/Antibody Drug Conjugates)

Regulatory Filings

  • Cumulative DMF filings: 92 DMFs filed till date
  • Developed market FDF filings: 2 product dossiers filed in H1, total 96 products filed cumulatively
  • 2 approvals received (including Tentative approvals) in H1

Capital Allocation and Dividend

  • CAPEX to Revenue reached 20% in H1 FY27
  • Declared Interim Dividend of ₹1.00 per share

Quality and ESG

  • Completed 59 Quality audits in H1 without critical findings
  • Making operational progress against SBTi-validated near-term GHG reduction targets
  • MSCI ESG rating: "BBB"

Corporate Details

  • Employees: 8,126 people including 3,134+ scientists
  • Facilities: 15 facilities approved by global regulators (USFDA, WHO, EMA, etc.)
  • FY2026 Revenue: ₹6,813 crore

Conference Call Details

  • Date: October 29, 2026 at 5:00 pm IST